Literature DB >> 8111568

Role of cysteinyl-leukotrienes and histamine in mediating intrinsic tone in isolated human bronchi.

J L Ellis1, B J Undem.   

Abstract

The intrinsic isometric tone of human isolated intralobar bronchi was evaluated in vitro. Human bronchi (inner diameter, 3 to 12 mm) were obtained from patients undergoing lung resection and from organ donors. The organ donor tissue was studied approximately 24 h after resection, during which time it was shipped to the laboratory in RPMI 1640 medium at 4 degrees C. The bronchi obtained from patients with cancer was placed in the same medium and studied within 4 h of resection. All tissues were suspended in 10-ml organ baths containing oxygenated Krebs' solution at 37 degrees C, at an initial load of 2 g. Tissues were washed every 15 min until they exhibited a stable tension (usually 60 min). Under these conditions the amount of active tension in the bronchi studied on the day of resection averaged 65 +/- 9% of the maximal response to BaCl2 (30 mM), whereas after overnight incubation it averaged 31 +/- 6%. Neither indomethacin nor atropine influenced the intrinsic tone in these tissues. By contrast, the LTD4 antagonists SKF 104353 and ICI 198615 and the histamine H-1 antagonists pyrilamine and chlorpheniramine effectively relaxed the bronchi. The 5' lipoxygenase inhibitor zileuton also produced a small fall in tension. Studies in which pyrilamine was combined with the leukotriene receptor antagonists indicated an additive effect. These results indicate that human bronchial smooth muscle exhibits a high degree of intrinsic tone, averaging more than 50% of available tone in fresh tissues studied in vitro under isometric conditions. The results suggest that this tone is due to the continual production and release of histamine and cysteinyl-leukotrienes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8111568     DOI: 10.1164/ajrccm.149.1.8111568

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  20 in total

Review 1.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

Review 2.  Adenosine receptors and asthma.

Authors:  R A Brown; D Spina; C P Page
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

Review 3.  Montelukast: a review of its therapeutic potential in asthma in children 2 to 14 years of age.

Authors:  Richard B R Muijsers; Stuart Noble
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 4.  Montelukast: a review of its therapeutic potential in persistent asthma.

Authors:  B Jarvis; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

5.  Endothelin-1 increases cholinergic nerve-mediated contraction of human bronchi via tachykinin synthesis induction.

Authors:  B D'Agostino; C Advenier; M Falciani; L Gallelli; G Marrocco; E Piegari; A Filippelli; F Rossi
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

6.  The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways.

Authors:  D T Schmidt; N Watson; G Dent; E Rühlmann; D Branscheid; H Magnussen; K F Rabe
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

7.  EndothelinB (ETB) receptor-activated potentiation of cholinergic nerve-mediated contraction in human bronchus.

Authors:  L B Fernandes; P J Henry; P J Rigby; R G Goldie
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 8.  The role of lung inflation in airway hyperresponsiveness and in asthma.

Authors:  Nicola Scichilone; Alkis Togias
Journal:  Curr Allergy Asthma Rep       Date:  2004-03       Impact factor: 4.806

Review 9.  Using guinea pigs in studies relevant to asthma and COPD.

Authors:  Brendan J Canning; Yangling Chou
Journal:  Pulm Pharmacol Ther       Date:  2008-02-02       Impact factor: 3.410

Review 10.  PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast.

Authors:  Victoria Boswell-Smith; Domenico Spina
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.